All Mass General Brigham articles
-
NewsTuberculosis vaccine changes brain’s immune environment and Alzheimer’s biomarkers in older adults
A study shows that BCG vaccines can alter immune responses and amyloid-beta biomarkers in non-Alzheimer’s participants, which may help explain previously observed links to lower disease risk.
-
NewsPreparing for Andes virus outbreaks to prevent transmission in healthcare settings
Researchers examined past cases to help healthcare facilities and public health agencies prepare for future Andes virus outbreaks like the one that caused a cruise ship outbreak earlier this year.
-
NewsLong Covid burden continues to grow, doubling current surveillance estimates, multi-hospital study shows
Investigators using a novel AI algorithm to comb through medical records of patients with COVID-19 in U.S. hospitals, found around one in six developed long COVID. These rates are twofold higher than current estimates.
-
NewsMillions suffering needlessly with curable hepatitis C, new analysis reveals
Millions of Americans are still battling potentially deadly hepatitis C even though they could be cured with antiviral drugs they are not receiving, a new analysis reveals.
-
NewsStandard-dose antibiotic the ‘preferred choice’ of treatment for uncomplicated acute sinusitis
A study of patients with acute sinusitis found no major differences in measured outcomes between adults who received standard amoxicillin and amoxicillin‑clavulanate. Patients treated with amoxicillin‑clavulanate were at slightly higher risk of contracting secondary infections.
-
NewsHigh‑fat diets linked to rapid decline in protective gut immune cells
In a preclinical study, researchers found that even short-term exposure to high levels of dietary fat results in a quick and selective loss of critical gut immune cells called ILC3s, promoting intestinal permeability and inflammation.
-
NewsDramatic reduction in prescribing of hepatitis C antivirals may leave many curable patients untreated
A new study analyzed a large national prescription database to estimate hepatitis C treatment courses over time and trends by patient and prescriber characteristics from 2013–2025. Prescriptions rose rapidly after direct-acting antivirals first became available, peaking in 2015, but then declined sharply through 2025.
-
NewsMulti-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
A global team of experts has identified a promising new approach to prevent recurrence of bacterial vaginosis (BV). In a phase 1 randomized clinical trial, researchers found that a short course of a multi-strain probiotic restored protective bacteria to the vagina, significantly reducing disease recurrence.
-
NewsTrial finds vitamin D supplements don’t reduce Covid severity but could reduce long COVID risk
In a large, randomized trial, researchers have found that high-dose vitamin D3 did not reduce COVID-19 infection severity, but may impact long COVID outcomes.
-
NewsVirus-based therapy boosts anti-cancer immune responses to brain cancer
A study has shown that a single injection of an oncolytic virus—a genetically modified virus that selectively infects and destroys cancer cells—can recruit immune cells to penetrate and persist deep within brain tumors.
-
NewsHow genes influence the microbes in our mouths
A new study has found human genetic factors that influence the oral microbiome and may increase risk of cavities and tooth loss in some people. Analysis of the now largest collection of oral microbiome profiles reveals interactions between human and bacterial DNA.
-
NewsWhat causes some people’s gut microbes to produce high alcohol levels?
A study of people with a rare condition known as auto-brewery syndrome has found a link between gut microbes and symptoms of intoxication, pointing to new treatment strategies.
-
NewsCholera vaccine completes phase 1 trial
A clinical trial shows promising results for PanChol, a single-dose oral vaccine aimed at the up to 4 million annual cholera cases worldwide.
-
NewsEngineered virus boosts immune response against glioblastoma in preclinical models
Researchers have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells. A single dose of the modified virus increased T-cell, natural killer cell, and myeloid cell responses in the tumor microenvironment and increased the overall survival in preclinical models.
-
NewsResearchers identify why some people with HIV achieve remission after antibody treatment
Researchers have discovered why some people living with HIV who are given broadly neutralizing anti-HIV antibodies (bNAbs) can safely stop taking standard, lifelong HIV medications and maintain control of the virus for years, while others given the same treatment do not achieve this remission.
-
NewsCOVID-19 during pregnancy linked to higher risk of neurodevelopmental disorders in children
Children born to mothers who had COVID-19 while pregnant face an elevated risk of developmental disorders by the time they turn 3 years old, including speech delays, autism, motor disorders, and other developmental delays, according to new research.
-
NewsStudy finds HEPA purifiers alone may not be enough to reduce viral exposure in schools
In a secondary analysis of a study of 200 classrooms, researchers found respiratory viral exposures were still high in those with HEPA purifiers, suggesting additional interventions are needed.
-
NewsBlood test identifies HPV-associated head and neck cancers up to 10 years before symptoms
Researchers show that a novel liquid biopsy tool called HPV-DeepSeek can identify HPV-associated head and neck cancer up to 10 years before symptoms appear.
-
NewsClinical trial finds safe, effective treatment for children with severe post-Covid syndrome
Researchers have discovered that a drug designed to treat Celiac disease supported a more rapid return to normal activities for patients following COVID. A small, randomized clinical trialfound the oral drug larazotide was both safe and effective in treating children with MIS-C.
-
NewsNew blood test shows superior sensitivity in detecting HPV-associated head and neck cancers
A new liquid biopsy blood test could help detect cases of human papillomavirus (HPV)-associated head and neck cancers with significantly higher accuracy than currently used methods, including before patients develop symptoms.